The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury

Anandharajan Rathinasabapathy, Alana Horowitz, Kelsey Horton, Ashok Kumar, Santhi Gladson, Thomas Unger, Diana Martinez, Gaurav Bedse, James West, Mohan K. Raizada, Ulrike M. Steckelings, Colin Sumners, Michael J. Katovich, Vinayak Shenoy

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number180
Number of pages11
JournalFrontiers in physiology
Volume9
DOIs
Publication statusPublished - 27 Mar 2018

Keywords

  • pulmonary fibrosis
  • pulmonary hypertension
  • C21
  • AT(2) receptor
  • bleomycin
  • rats
  • RATS
  • PIRFENIDONE
  • FIBROBLASTS
  • ACTIVATION
  • DISEASE
  • STROKE
  • SYSTEM
  • CELLS

Cite this

Rathinasabapathy, A., Horowitz, A., Horton, K., Kumar, A., Gladson, S., Unger, T., Martinez, D., Bedse, G., West, J., Raizada, M. K., Steckelings, U. M., Sumners, C., Katovich, M. J., & Shenoy, V. (2018). The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in physiology, 9, [180]. https://doi.org/10.3389/fphys.2018.00180